经皮经肝胆管造影中胰管显影与胰腺炎相关性的初步研究
|
摘要
目的
恶性梗阻性黄疸(malignant biliary obstruction, MOJ)主要由胰头癌、胆囊癌、胆管癌以及转移性肿瘤如胃癌胆道转移压迫或侵蚀胆管所致,主要表现为皮肤黏膜及巩膜黄染,可以造成机体一系列病理生理紊乱,如免疫功能下降,凝血功能障碍、心功能降低、营养不良等,随着病情逐渐加重可引起肝肾功能衰竭,甚至死亡。自1974年Molnar和Stocknm创立经皮经肝胆道引流术(Percutaneous transhepatic cholangial drainage, PTCD)缓解恶性梗阻性黄疸以来,PTCD及胆道支架置入术作为微创技术已经成为姑息性治疗恶性梗阻性黄疸最常用的方法。不宜手术患者采用PTCD或／和胆道支架置入术进行治疗,可有效缓解恶性梗阻性黄疸症状、延长患者的生存期及提高患者的生活质量。但是以往研究显示,实施PTCD或／和胆道支架置入术后合并的并发症会影响治疗效果,甚至会导致患者死亡。其中,术后合并胰腺炎是较为严重的并发症之一。在经皮经肝胆管造影术中,当造影了解治疗(胆道引流和／或内支架置入)后胆道通畅情况时,有时可见到胆管、胰管同时显影；而正常情况下由于胆胰管均受Oddi括约肌控制,彼此不相交通,且胆管内压力高于十二指肠内压力,胰管内压力又高于胆管,胰管并不显影。
本研究通过对2008年9月-2009年9月中国医科大学附属盛京医院经介入治疗的梗阻性黄疸患者的临床资料进行回顾性分析,旨在初步分析经皮经肝胆管造影术中胰管显影与术后胰腺炎相关性的关系。
资料与方法
收集2008年9月至2009年9月间连续82例因梗阻性黄疸于我科经PTC行介入治疗的病人的临床及影像学资料。确立病例纳入标准及排除标准,从中筛选出符合标准的病例70例。其中,男44例,女26例,年龄28-88岁,平均67.6±12.6岁。临床表现主要有无痛性不同程度皮肤粘膜及巩膜黄染伴皮肤瘙痒、食欲减退、小便黄、大便陶土色。所有患者均经CT和／或MR检查诊断为恶性胆道梗阻。化验室检查主要为肝功能测定,包括总胆红素(total bilirubin, TBIL)、直接胆红素(direct bilirubin, DBIL)、间接胆红素(indirect bilirubin, IBIL)、谷草转氨酶(aspartate aminotransferase, AST)、谷丙转氨酶(alanine aminotransferase, ALT)及白蛋白(albumin, ALB)。
所有患者均先行经皮经肝胆道穿刺,随后置入引流管行胆道引流或胆道内支架。术后密切观察患者的皮肤粘膜颜色、尿色便色、腹部体征及体征的变化,1周后行化验复查。所有检查数据输入SPSS 13.0软件完成统计学处理。
结果
1、全部70例患者成功穿刺并置入引流管,其中仅行PTCD18例,胆管支架置入52例,成功率100%。总胆红素、直接胆红素及间接胆红素水平均有不同程度的下降；白蛋白水平亦有明显下降。
2、全部70例患者中,术后合并胰腺炎患者9例,发病率为12.9%。术中胆管造影过程中,胰管显影病例与胰管未显影病例组胰腺炎发病差异具有统计学意义,术中胰管显影组胰腺炎发病率高于胰管未显影组；Spearman相关分析得,术中胰管显影与术后合并胰腺炎呈正相关。
结论
经皮经肝胆管造影中胰管显影组与未显影组,术后胰腺炎的发生率存在差异,具有统计学意义,术中胰管显影组术后胰腺炎的发生率高于胰管未显影组；术中胰管显影与术后合并胰腺炎呈正相关。
Objective
Malignant obstructive jaundice is caused mainly by pancreatic cancer, gallbladder cancer, cholangiocarcinoma,and metastatic tumors such as biliary duct metastasis of gastric cancer. The main clinical manifestations of malignant obstructive jaundice are stained yellow skin and mucosa and sclera, which can cause the body a series of physiological and pathological disorders such as decreased immune function, blood coagulation dysfunction, decreased cardiac function, malnutrition, etc. As the disease gradually worsened, malignant obstructive jaundice can cause liver and kidney failure and even death. Since founded in 1974, Molnar and Stocknm percutaneous biliary drainage for malignant obstructive jaundice remission since, PTCD and biliary stent placement as a minimally invasive technique has become the palliative treatment of malignant obstructive jaundice the most common method. PTCD or/and biliary stent placement can effectively relieve malignant obstructive jaundice symptoms, prolong survival and improve quality of life of patients who should not be treated with surgery. However, previous studies showed that the complications of PTCD and/or biliary stent placement can affect the treatment, and even lead to death. Which, the pancreatitis after PTCD or/and biliary stent placement is one of the more serious complications. In percutaneous transhepatic cholangiography, when imaging to understand the case of biliary patency after the treatment(biliary drainage and/or stent), sometimes we can see bile duct and pancreatic duct develop at the same time. Normally, bile duct and pancreatic duct do not connect with each other,which are subject to control of Oddi sphincter.The pressure in bile duct is higher than the pressure in the duodenum, and the pressure in pancreatic duct is higher than the pressure in the bile duct, so when cholangiography, the pancreatic duct does not develop.
This study aims at retrospectively analyzing the clinical data of the patients with obstructive jaundice who were treated by intervention in Shengjing Hospital of China Medical University between September 2008 and September 2009 to analysis the relationship between the visualization of pancreatic duct in percutaneous transhepatic cholangiography and the pancreatitis preliminarily.
Materials and Methods
Collecting the clinical data of consecutive 82 Patients with obstructive jaundice(OJ) are receiving the Interventional therapy in our hospital from September 2008 to September 2009. Clinical findings and cholangiopancreatographic results were analyzed. Meanwhile the standard to be selected for cases and the criteria for exclusion were established,70 patients selected. Among them,44 males and 26 females, aged 28 to 88 years,the average age of whom was 67.6±12.6 years. The main clinical manifestations of malignant obstructive jaundice are different degrees of painless stained yellow skin and mucosa and sclera, loss of appetite, yellow urine, clay colored stools. All patients was diagnosed with malignant biliary obstruction by CT and/or MR. Laboratory examination of liver function is mainly determined, including TBIL,DBIL,IBIL,AST,ALT andAlb.
All patients were underwent percutaneous transhepatic puncture befor PTCD and biliary stent placement. After interventional therapy, the skin color, urine color, stool color, abdominal signs and changes of symptoms are the major observation,the test review after 1 weeks. All of the data are analyzed by SPSS 13.0 statistical package.
Results
1、PTCD or/and biliary stent placement were performed successful for all patients.Among them,only 18 cases received PTCD, meanwhile,52 cases accepted biliary stent placement,100% success rate.The levels of TBIL,DBIL,IBIL,AST,ALT were in decline,and the levels of albumin also decreased significantly.
2、Among all 70 patients,9 patients with pancreatitis occurred.The incidence rate was 12.9%. The incidence rate of pancreatitis of two cases were significant. The incidence of pancreatitis of the patients whose pancreatic duct intraoperative visualization was higher than that of pancreatic duct don't develop. Spearman analysis of correlation show that there is positive correlation between the visualization of pancreatic duct in the operation of Cholescintigraphy and the pancreatitis after the operation of Cholescintigraphy.
Conclusion
The incidence of pancreatitis of the patients whose pancreatic duct intraoperative visualization was higher than that of pancreatic duct don't develop.There is positive correlation between the visualization of pancreatic duct in the operation of Cholescintigraphy and the pancreatitis after the operation of Cholescintigraphy.
恶性梗阻性黄疸(malignant biliary obstruction, MOJ)主要由胰头癌、胆囊癌、胆管癌以及转移性肿瘤如胃癌胆道转移压迫或侵蚀胆管所致,主要表现为皮肤黏膜及巩膜黄染,可以造成机体一系列病理生理紊乱,如免疫功能下降,凝血功能障碍、心功能降低、营养不良等,随着病情逐渐加重可引起肝肾功能衰竭,甚至死亡。自1974年Molnar和Stocknm创立经皮经肝胆道引流术(Percutaneous transhepatic cholangial drainage, PTCD)缓解恶性梗阻性黄疸以来,PTCD及胆道支架置入术作为微创技术已经成为姑息性治疗恶性梗阻性黄疸最常用的方法。不宜手术患者采用PTCD或／和胆道支架置入术进行治疗,可有效缓解恶性梗阻性黄疸症状、延长患者的生存期及提高患者的生活质量。但是以往研究显示,实施PTCD或／和胆道支架置入术后合并的并发症会影响治疗效果,甚至会导致患者死亡。其中,术后合并胰腺炎是较为严重的并发症之一。在经皮经肝胆管造影术中,当造影了解治疗(胆道引流和／或内支架置入)后胆道通畅情况时,有时可见到胆管、胰管同时显影；而正常情况下由于胆胰管均受Oddi括约肌控制,彼此不相交通,且胆管内压力高于十二指肠内压力,胰管内压力又高于胆管,胰管并不显影。
本研究通过对2008年9月-2009年9月中国医科大学附属盛京医院经介入治疗的梗阻性黄疸患者的临床资料进行回顾性分析,旨在初步分析经皮经肝胆管造影术中胰管显影与术后胰腺炎相关性的关系。
资料与方法
收集2008年9月至2009年9月间连续82例因梗阻性黄疸于我科经PTC行介入治疗的病人的临床及影像学资料。确立病例纳入标准及排除标准,从中筛选出符合标准的病例70例。其中,男44例,女26例,年龄28-88岁,平均67.6±12.6岁。临床表现主要有无痛性不同程度皮肤粘膜及巩膜黄染伴皮肤瘙痒、食欲减退、小便黄、大便陶土色。所有患者均经CT和／或MR检查诊断为恶性胆道梗阻。化验室检查主要为肝功能测定,包括总胆红素(total bilirubin, TBIL)、直接胆红素(direct bilirubin, DBIL)、间接胆红素(indirect bilirubin, IBIL)、谷草转氨酶(aspartate aminotransferase, AST)、谷丙转氨酶(alanine aminotransferase, ALT)及白蛋白(albumin, ALB)。
所有患者均先行经皮经肝胆道穿刺,随后置入引流管行胆道引流或胆道内支架。术后密切观察患者的皮肤粘膜颜色、尿色便色、腹部体征及体征的变化,1周后行化验复查。所有检查数据输入SPSS 13.0软件完成统计学处理。
结果
1、全部70例患者成功穿刺并置入引流管,其中仅行PTCD18例,胆管支架置入52例,成功率100%。总胆红素、直接胆红素及间接胆红素水平均有不同程度的下降；白蛋白水平亦有明显下降。
2、全部70例患者中,术后合并胰腺炎患者9例,发病率为12.9%。术中胆管造影过程中,胰管显影病例与胰管未显影病例组胰腺炎发病差异具有统计学意义,术中胰管显影组胰腺炎发病率高于胰管未显影组；Spearman相关分析得,术中胰管显影与术后合并胰腺炎呈正相关。
结论
经皮经肝胆管造影中胰管显影组与未显影组,术后胰腺炎的发生率存在差异,具有统计学意义,术中胰管显影组术后胰腺炎的发生率高于胰管未显影组；术中胰管显影与术后合并胰腺炎呈正相关。
Objective
Malignant obstructive jaundice is caused mainly by pancreatic cancer, gallbladder cancer, cholangiocarcinoma,and metastatic tumors such as biliary duct metastasis of gastric cancer. The main clinical manifestations of malignant obstructive jaundice are stained yellow skin and mucosa and sclera, which can cause the body a series of physiological and pathological disorders such as decreased immune function, blood coagulation dysfunction, decreased cardiac function, malnutrition, etc. As the disease gradually worsened, malignant obstructive jaundice can cause liver and kidney failure and even death. Since founded in 1974, Molnar and Stocknm percutaneous biliary drainage for malignant obstructive jaundice remission since, PTCD and biliary stent placement as a minimally invasive technique has become the palliative treatment of malignant obstructive jaundice the most common method. PTCD or/and biliary stent placement can effectively relieve malignant obstructive jaundice symptoms, prolong survival and improve quality of life of patients who should not be treated with surgery. However, previous studies showed that the complications of PTCD and/or biliary stent placement can affect the treatment, and even lead to death. Which, the pancreatitis after PTCD or/and biliary stent placement is one of the more serious complications. In percutaneous transhepatic cholangiography, when imaging to understand the case of biliary patency after the treatment(biliary drainage and/or stent), sometimes we can see bile duct and pancreatic duct develop at the same time. Normally, bile duct and pancreatic duct do not connect with each other,which are subject to control of Oddi sphincter.The pressure in bile duct is higher than the pressure in the duodenum, and the pressure in pancreatic duct is higher than the pressure in the bile duct, so when cholangiography, the pancreatic duct does not develop.
This study aims at retrospectively analyzing the clinical data of the patients with obstructive jaundice who were treated by intervention in Shengjing Hospital of China Medical University between September 2008 and September 2009 to analysis the relationship between the visualization of pancreatic duct in percutaneous transhepatic cholangiography and the pancreatitis preliminarily.
Materials and Methods
Collecting the clinical data of consecutive 82 Patients with obstructive jaundice(OJ) are receiving the Interventional therapy in our hospital from September 2008 to September 2009. Clinical findings and cholangiopancreatographic results were analyzed. Meanwhile the standard to be selected for cases and the criteria for exclusion were established,70 patients selected. Among them,44 males and 26 females, aged 28 to 88 years,the average age of whom was 67.6±12.6 years. The main clinical manifestations of malignant obstructive jaundice are different degrees of painless stained yellow skin and mucosa and sclera, loss of appetite, yellow urine, clay colored stools. All patients was diagnosed with malignant biliary obstruction by CT and/or MR. Laboratory examination of liver function is mainly determined, including TBIL,DBIL,IBIL,AST,ALT andAlb.
All patients were underwent percutaneous transhepatic puncture befor PTCD and biliary stent placement. After interventional therapy, the skin color, urine color, stool color, abdominal signs and changes of symptoms are the major observation,the test review after 1 weeks. All of the data are analyzed by SPSS 13.0 statistical package.
Results
1、PTCD or/and biliary stent placement were performed successful for all patients.Among them,only 18 cases received PTCD, meanwhile,52 cases accepted biliary stent placement,100% success rate.The levels of TBIL,DBIL,IBIL,AST,ALT were in decline,and the levels of albumin also decreased significantly.
2、Among all 70 patients,9 patients with pancreatitis occurred.The incidence rate was 12.9%. The incidence rate of pancreatitis of two cases were significant. The incidence of pancreatitis of the patients whose pancreatic duct intraoperative visualization was higher than that of pancreatic duct don't develop. Spearman analysis of correlation show that there is positive correlation between the visualization of pancreatic duct in the operation of Cholescintigraphy and the pancreatitis after the operation of Cholescintigraphy.
Conclusion
The incidence of pancreatitis of the patients whose pancreatic duct intraoperative visualization was higher than that of pancreatic duct don't develop.There is positive correlation between the visualization of pancreatic duct in the operation of Cholescintigraphy and the pancreatitis after the operation of Cholescintigraphy.
引文
1刘小方,周先亭,邹声泉.八所医院胆管癌680例分析[J].中华肝胆外科杂志.2004；10(11):773-775.
2王炳生,秦净,邓杰,等.上海市胆道癌诊治情况的调查和分析[J].中华外科杂志.2005;43(7):455-459.
3封光华,蔡阳,杨德琪,等.恶性梗阻性黄疸介入治疗[J].消化外科.2002;1(3):193-194.
4韩新巍.积极开展阻塞性黄疸的介入放射学病例诊断及综合治疗[J].介入放射学杂志.2002;11(5):322-323.
5 Bahra M, Jacob D. Surgical palliation of advanced pancreatic cancer. Recent Results Cancer Res.2008; 177:111-120.
6 Lee BH, Choe DH, Lee JH, et al. Metallic stents in malignant biliary obstructiong prospective long-term clinical results. AJR Am J Rocntgenol.1997;168(3):741-745.
7李茂全,张家兴,陆晨晖,等.恶性梗阻性黄疸介入综合治疗[J].中华医学杂志.2008;88(39):2743-2747.
8夏永辉,徐克,苏洪英,等.晚期恶性梗阻性黄疸经皮介入治疗近期并发症的临床观察及处理[J].中国介入放射学.2009;1(3):88-90.
9李臻,韩新巍,张伟,等.阻塞性黄疸经皮经肝胆管引流术中胰管显影的原因分析[J].介入放射学杂志.2008;11(17):806-808.
10肖现民.不断加深对胰胆管合流异常的认识[J].中华肝胆外科杂志.2003;11(3):161-162.
11陈其奎.奥迪括约肌运动功能失调[J].新医学.2000;31(11):650-651.
12周存才,李占元,曾庆东,等.胰胆管合流异常的术后胆道造影表现[J].放射学实践.2005；20(8):679-682.
13周存才,李占元,曾庆东,等.术后胆道造影诊断胰胆管合流异常18例临床分析[J].中华外科杂志.2006;44(5):336-337.
14姜卫剑,姚力,任安,等.经皮胆道内支架置入术姑息性治疗恶性梗阻性黄疸[J].中华放射学杂志.1997;31(11)：6-10.
15 Christensen M, Matzen P, Schulze S, et al. Complication of ERCP:a prospective study. Gastrointest Endosc.2004; 60(7):721-31.
16 Leung J T, Kuan R. Intraluminal brachytherapy in the treatment of bile duct carcinomas. A ustralas Radiol.1997;41:151.
17 Bruha R, Petrtyl J, Kubecova M, et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies-the question of long-term palliation. Hepato Gastroenterology.2001;48:637.
18 Kubota Y, Kin H, Tokaoka M, et al. Endoscopic irradiation and parallel arrangement of Wallstents for hilar cholangiocarcinoma. Hepato Gastroenterology.1998;45:415.
19 Rumalla A, Baron TH. Evaluation and endoscopic palliation of Cholangiocarcinoma. Dig Dis. 1999;17(4):194-200.
20 Gunven P, Gorsetman D, Ohlsen H, et al. Six-year recurrence free survival aftert Intraluminal Iridium-192 therapy of human bilobar biliary papillomatosis:A case report. Cancer. 2000;89(1):69-73.
21 Montemaggi P, Morganti A, Dobelbower R, et al. Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers:is it just for palliation? Radiology. 1996;1999:861.
22 Merimsky O, Nori D, Rogers D, et al. Comformal high dose rate percutaneous transhepatic intraluminal cholangio-irradiation for unresectable cholangiocharcinoma. Endocuriether Hyperthermia Oncol.1995;11:115.
1刘小方,周先亭,邹声泉.八所医院胆管癌680例分析.中华肝胆外科杂志,2004.10(11):773-775.
2王炳生,秦净,邓杰,等.上海市胆道癌诊治情况的调查和分析.中华外科杂志,2005.43(7):455-459.
3周宁新,刘永雄,黄志强.肝外胆管癌1098例分析.中华外科杂志.1990.28:518-521.
4钱晓军,仁友,戴定可,等.老年人恶性梗阻性黄疸介入治疗回顾性分析.中华放射学杂志.2000.34(5):342-345.
5翟仁友,戴定可,于平,钱小军,王剑锋.重视PTBD并发症的预防和处理.中国介入放射学.2008.02(02)：104-105.
6 G. Molinari, V. pugliese, C. A. Guzman, et al. Bacteria Involved in the Blockage of Biliary Stents and Their Susceptibility to Antibacterial Agents. Eur. J. Clin. Microbiol. Infect. Dis. 1996.15(1):88-92.
7 Frank Schmal. MD, Wolfgang Fegeler. MD, Hans Joachim Terpe, et al. Bacteria and Granulation Tissue ssociated With Montgomery T-Tubes. Laryngoscope.2003; 113(8):
8 1394-1400.
9 Hongjun Zhang. PhD, MD, et al. Inhibition of Bacterial Adherence on the Surface of Stents and Bacterial Growth in Bile by Bismuth imercaprol. Digestive Diseases and Sciences. 2005;50(6):1046-1051.
10 JJY Sung. Bacterial biofilm and clogging of biliary stents. Journal of Industrial Microbiology. 1995.15(3):152-155.
11 Leung JW, Liu YL, Desta T, et al. Is there a synergistic effect between mixed bacterial infection in biofilm formation on biliary stents? Gastrointest Endosc 1998.48(3):250-257.
12 Groan AK, T Out, K Huibregtse et al. Characterization of the content of occluded biliary endoprosthesis. Endoscopy.1987.19 (2):57-59.
13 Leung JWC, TKW Ling, KL Kung et al. Early attachment of anaerobic bacteria may play an important role in biliary stent blockage. Gastroint Endosc.2000.52(6):725-9.
14 Speer A, PB Cotton, J Rode et al. Biliary stent blockage with bacterial biofilm: a light and electron microscopy. Ann Intern Med 1988.108(4):546-53.
15 Smit JM, MM Out, AK Groen et al. A placebo-controlled study on the efficacy of aspirin and doxycycline in preventing clogging of biliary endoprosthesis. Gastroint Endosc. 1989.35(6): 485-489.
16 Joseph W. Leung, MD, FRCP, Eric D. Libby, MD, Douglas W. Morck, DVM, PhD etal. Gastrointest Endosc.2000.52:175-182.
17 Ghosh S and KR Palmer. Prophylaxis of biliary stent blockage using cyclical antibiotics and
ursodeoxycholic acid. Gastroenterology.1993.104:A361
18 Costerton JW, Z Lewandowski, D DeBeer et al. Biofilms:the customized microniche. J Bacteriol.1994.176(8):2137-2142.
19 Sung JY, EA Shaffer, I. RUSUSKA and JW Costerton. Hydrophobic Bile Salt Inhibits Bacterial Adhesion on Biliary Stent Material. Digestive Diseases and Sciences.1994.39(5): 999-1006.
20 Zhang HJ, Tang J, Meng XW, et al. Inhibition of Bacterial Adherence on the Surface of Stents and Bacterial Growth in Bile by Bismuth Dimercaprol. Digestive Diseases and Sciences. 2005.50(6):1046-1051.
21 Costa Costa L, Bracco P, Vada S, Trossarelli L, Jacobson K. A. Chemical analysis of the clogging process of polymeric biliary endoprostheses. Biomaterials.2001.22(23):3113-3119.
22 Speer AG, Cotton PB, MacRae KD. Endoscopic management of malignant biliary obstruction: stents of 10 French gauge are preferable to stents of 8 French gauge. Gastrointest Endosc. 1988.34(5):412-417.
23 O'Brien S, Hatfield AR, Craig PI, Williams SP. A three year follow up of self expanding metal stents in the endoscopic palliation of longterm survivors with malignant biliary obstruction. Gut.1995.36(4):618-621.
24 van Berkel AM, Bergman JJ, Waxman I, et al. Wallstents for metastatic biliary obstruction. Endoscopy.1996.28(5):418-421.
25 Dowidar N, HJ Kolmos, H Lyon et al. Clogging of biliary endoprosthesis:a morphologic and bacteriologic study. Scand J Gastroenterol.1991.26(11):1137-1144.
26 Sung JY, SCS Chung, CP Tsui et al. Omitting side-holes in biliary stents does not improve drainage of the obstructed biliary system:a prospective randomized trial. Gastroint Endosc. 1994.40(2):321-25.
27 Finn M(?)ller Pedersen, Annmarie Touborg Lassen. Randomized trial of stent placed above and across the sphincter of Oddi in malignant bile duct obstruction. Gastrointest Endosc.1998. 48(6):574-579.
28 Kulwinder S. Dua, Nageshwar D. Reddy Venkat G. Rao, et al. Impact of reducing duodenobiliary reflux on biliary stent patency:an in vitro evaluation and a prospective randomized clinical trial that used a biliary stent with an antireflux valve. Gastrointest Endosc. 2007.65(6):819-28.
2王炳生,秦净,邓杰,等.上海市胆道癌诊治情况的调查和分析[J].中华外科杂志.2005;43(7):455-459.
3封光华,蔡阳,杨德琪,等.恶性梗阻性黄疸介入治疗[J].消化外科.2002;1(3):193-194.
4韩新巍.积极开展阻塞性黄疸的介入放射学病例诊断及综合治疗[J].介入放射学杂志.2002;11(5):322-323.
5 Bahra M, Jacob D. Surgical palliation of advanced pancreatic cancer. Recent Results Cancer Res.2008; 177:111-120.
6 Lee BH, Choe DH, Lee JH, et al. Metallic stents in malignant biliary obstructiong prospective long-term clinical results. AJR Am J Rocntgenol.1997;168(3):741-745.
7李茂全,张家兴,陆晨晖,等.恶性梗阻性黄疸介入综合治疗[J].中华医学杂志.2008;88(39):2743-2747.
8夏永辉,徐克,苏洪英,等.晚期恶性梗阻性黄疸经皮介入治疗近期并发症的临床观察及处理[J].中国介入放射学.2009;1(3):88-90.
9李臻,韩新巍,张伟,等.阻塞性黄疸经皮经肝胆管引流术中胰管显影的原因分析[J].介入放射学杂志.2008;11(17):806-808.
10肖现民.不断加深对胰胆管合流异常的认识[J].中华肝胆外科杂志.2003;11(3):161-162.
11陈其奎.奥迪括约肌运动功能失调[J].新医学.2000;31(11):650-651.
12周存才,李占元,曾庆东,等.胰胆管合流异常的术后胆道造影表现[J].放射学实践.2005；20(8):679-682.
13周存才,李占元,曾庆东,等.术后胆道造影诊断胰胆管合流异常18例临床分析[J].中华外科杂志.2006;44(5):336-337.
14姜卫剑,姚力,任安,等.经皮胆道内支架置入术姑息性治疗恶性梗阻性黄疸[J].中华放射学杂志.1997;31(11)：6-10.
15 Christensen M, Matzen P, Schulze S, et al. Complication of ERCP:a prospective study. Gastrointest Endosc.2004; 60(7):721-31.
16 Leung J T, Kuan R. Intraluminal brachytherapy in the treatment of bile duct carcinomas. A ustralas Radiol.1997;41:151.
17 Bruha R, Petrtyl J, Kubecova M, et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies-the question of long-term palliation. Hepato Gastroenterology.2001;48:637.
18 Kubota Y, Kin H, Tokaoka M, et al. Endoscopic irradiation and parallel arrangement of Wallstents for hilar cholangiocarcinoma. Hepato Gastroenterology.1998;45:415.
19 Rumalla A, Baron TH. Evaluation and endoscopic palliation of Cholangiocarcinoma. Dig Dis. 1999;17(4):194-200.
20 Gunven P, Gorsetman D, Ohlsen H, et al. Six-year recurrence free survival aftert Intraluminal Iridium-192 therapy of human bilobar biliary papillomatosis:A case report. Cancer. 2000;89(1):69-73.
21 Montemaggi P, Morganti A, Dobelbower R, et al. Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers:is it just for palliation? Radiology. 1996;1999:861.
22 Merimsky O, Nori D, Rogers D, et al. Comformal high dose rate percutaneous transhepatic intraluminal cholangio-irradiation for unresectable cholangiocharcinoma. Endocuriether Hyperthermia Oncol.1995;11:115.
1刘小方,周先亭,邹声泉.八所医院胆管癌680例分析.中华肝胆外科杂志,2004.10(11):773-775.
2王炳生,秦净,邓杰,等.上海市胆道癌诊治情况的调查和分析.中华外科杂志,2005.43(7):455-459.
3周宁新,刘永雄,黄志强.肝外胆管癌1098例分析.中华外科杂志.1990.28:518-521.
4钱晓军,仁友,戴定可,等.老年人恶性梗阻性黄疸介入治疗回顾性分析.中华放射学杂志.2000.34(5):342-345.
5翟仁友,戴定可,于平,钱小军,王剑锋.重视PTBD并发症的预防和处理.中国介入放射学.2008.02(02)：104-105.
6 G. Molinari, V. pugliese, C. A. Guzman, et al. Bacteria Involved in the Blockage of Biliary Stents and Their Susceptibility to Antibacterial Agents. Eur. J. Clin. Microbiol. Infect. Dis. 1996.15(1):88-92.
7 Frank Schmal. MD, Wolfgang Fegeler. MD, Hans Joachim Terpe, et al. Bacteria and Granulation Tissue ssociated With Montgomery T-Tubes. Laryngoscope.2003; 113(8):
8 1394-1400.
9 Hongjun Zhang. PhD, MD, et al. Inhibition of Bacterial Adherence on the Surface of Stents and Bacterial Growth in Bile by Bismuth imercaprol. Digestive Diseases and Sciences. 2005;50(6):1046-1051.
10 JJY Sung. Bacterial biofilm and clogging of biliary stents. Journal of Industrial Microbiology. 1995.15(3):152-155.
11 Leung JW, Liu YL, Desta T, et al. Is there a synergistic effect between mixed bacterial infection in biofilm formation on biliary stents? Gastrointest Endosc 1998.48(3):250-257.
12 Groan AK, T Out, K Huibregtse et al. Characterization of the content of occluded biliary endoprosthesis. Endoscopy.1987.19 (2):57-59.
13 Leung JWC, TKW Ling, KL Kung et al. Early attachment of anaerobic bacteria may play an important role in biliary stent blockage. Gastroint Endosc.2000.52(6):725-9.
14 Speer A, PB Cotton, J Rode et al. Biliary stent blockage with bacterial biofilm: a light and electron microscopy. Ann Intern Med 1988.108(4):546-53.
15 Smit JM, MM Out, AK Groen et al. A placebo-controlled study on the efficacy of aspirin and doxycycline in preventing clogging of biliary endoprosthesis. Gastroint Endosc. 1989.35(6): 485-489.
16 Joseph W. Leung, MD, FRCP, Eric D. Libby, MD, Douglas W. Morck, DVM, PhD etal. Gastrointest Endosc.2000.52:175-182.
17 Ghosh S and KR Palmer. Prophylaxis of biliary stent blockage using cyclical antibiotics and
ursodeoxycholic acid. Gastroenterology.1993.104:A361
18 Costerton JW, Z Lewandowski, D DeBeer et al. Biofilms:the customized microniche. J Bacteriol.1994.176(8):2137-2142.
19 Sung JY, EA Shaffer, I. RUSUSKA and JW Costerton. Hydrophobic Bile Salt Inhibits Bacterial Adhesion on Biliary Stent Material. Digestive Diseases and Sciences.1994.39(5): 999-1006.
20 Zhang HJ, Tang J, Meng XW, et al. Inhibition of Bacterial Adherence on the Surface of Stents and Bacterial Growth in Bile by Bismuth Dimercaprol. Digestive Diseases and Sciences. 2005.50(6):1046-1051.
21 Costa Costa L, Bracco P, Vada S, Trossarelli L, Jacobson K. A. Chemical analysis of the clogging process of polymeric biliary endoprostheses. Biomaterials.2001.22(23):3113-3119.
22 Speer AG, Cotton PB, MacRae KD. Endoscopic management of malignant biliary obstruction: stents of 10 French gauge are preferable to stents of 8 French gauge. Gastrointest Endosc. 1988.34(5):412-417.
23 O'Brien S, Hatfield AR, Craig PI, Williams SP. A three year follow up of self expanding metal stents in the endoscopic palliation of longterm survivors with malignant biliary obstruction. Gut.1995.36(4):618-621.
24 van Berkel AM, Bergman JJ, Waxman I, et al. Wallstents for metastatic biliary obstruction. Endoscopy.1996.28(5):418-421.
25 Dowidar N, HJ Kolmos, H Lyon et al. Clogging of biliary endoprosthesis:a morphologic and bacteriologic study. Scand J Gastroenterol.1991.26(11):1137-1144.
26 Sung JY, SCS Chung, CP Tsui et al. Omitting side-holes in biliary stents does not improve drainage of the obstructed biliary system:a prospective randomized trial. Gastroint Endosc. 1994.40(2):321-25.
27 Finn M(?)ller Pedersen, Annmarie Touborg Lassen. Randomized trial of stent placed above and across the sphincter of Oddi in malignant bile duct obstruction. Gastrointest Endosc.1998. 48(6):574-579.
28 Kulwinder S. Dua, Nageshwar D. Reddy Venkat G. Rao, et al. Impact of reducing duodenobiliary reflux on biliary stent patency:an in vitro evaluation and a prospective randomized clinical trial that used a biliary stent with an antireflux valve. Gastrointest Endosc. 2007.65(6):819-28.